SLC9C2: A Potential Drug Target for Type 2 Diabetes (G284525)

Target Name: SLC9C2

NCBI ID: G284525

SLC9C2

SLC9C2: A Potential Drug Target for Type 2 Diabetes

SLC9C2 (SL9C2_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the sulfate transport family 9, which includes proteins that transport sulfates across cell membranes. SLC9C2 is also known as GLUT2, which stands for glucose-regulated transport protein 2.

SLC9C2 is a potential drug target because of its role in the regulation of glucose metabolism. It is expressed in the brain, which is the most important organ for glucose metabolism, and it is involved in the uptake and release of glucose. SLC9C2 is also involved in the regulation of insulin sensitivity, which is critical for the development and progression of type 2 diabetes.

SLC9C2 is a transmembrane protein, which means that it spans the cell membrane and is expressed in the cell's outer layer. It is composed of four distinct subunits, which are arranged in a specific order to form a monomeric protein. The first and last subunits The base contains a catalytic active site, which is responsible for the protein's unique structure and function. The second and second-last subunits contain a transmembrane region, which allows the protein to interact with various cellular signaling pathways.

SLC9C2 is involved in the transport of sulfates across cell membranes. Sulfates are important for various cellular processes, including energy metabolism, signaling, and inflammation. They are also involved in the regulation of various cellular processes, including cell growth, differentiation, and inflammation. SLC9C2 is specifically involved in the uptake and release of glucose, which is a critical source of energy for the brain.

SLC9C2 is also involved in the regulation of insulin sensitivity. Insulin is a hormone that is produced by the pancreas and helps to regulate the body's blood sugar levels. When the body's blood sugar levels are high, insulin is released to help regulate them. However, in people with type 2 diabetes, the body is less able to produce or respond to insulin, which can lead to high blood sugar levels. SLC9C2 is involved in the regulation of insulin sensitivity by controlling the uptake and release of glucose into the body's cells.

SLC9C2 is also a potential biomarker for the diagnosis and progression of type 2 diabetes. Type 2 diabetes is a chronic autoimmune disease that is characterized by the body's inability to produce or respond to insulin. It is a leading cause of death and disability in the world , and it is a major cause of healthcare costs. SLC9C2 may be a useful biomarker for the diagnosis and progression of type 2 diabetes because it is involved in the regulation of insulin sensitivity, which is a key factor in the development of the disease.

In conclusion, SLC9C2 is a protein that is expressed in various tissues of the human body and is involved in the regulation of glucose metabolism and insulin sensitivity. It may be a useful drug target or biomarker for the diagnosis and progression of type 2 diabetes. Further research is needed to fully understand the role of SLC9C2 in these processes and to develop effective treatments for this important disease.

Protein Name: Solute Carrier Family 9 Member C2 (putative)

Functions: Involved in pH regulation

The "SLC9C2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC9C2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets